US must meet tougher standard in Regeneron kickback lawsuit
Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's third consecutive day of gains.
3REGN : Price Over Earnings Overview: Regeneron Pharmaceuticals
In the current market session, Regeneron Pharmaceuticals Inc. REGN share price is at $695.58, after a 0.06% decrease. Over the past month, the stock spiked by 2.93%, but over the past year, it ...
Fat, not muscle: drugmakers in race for next weight-loss breakthrough
European Union trade chief Maros Sefcovic said on Thursday that his top priority in trade talks with President Donald Trump's ...
GlobalData on MSN3d
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
Healio3h
FDA accepts sBLA, grants priority review for Dupixent to treat bullous pemphigoid
The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been ...
JD Supra19h
False Claim Act Liability Under Anti-Kickback Statute Requires But-For Causation: First Circuit Narrows Liability in Growing Circuit Split
On February 18, 2025, the First Circuit Court of Appeals issued its decision in U.S. v. Regeneron Pharmaceuticals, ruling ...
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman
Regeneron is also embroiled in a securities fraud class action lawsuit stemming from a significant stock price drop on October 31, 2024. Shares plunged $84.59 that day, wiping out approximately $9 ...
JD Supra4h
First Circuit Requires But-For Causation for FCA Liability Based on AKS Violations
Key Takeaways - The First Circuit ruled in United States v. Regeneron Pharmaceuticals, Inc., that the government must prove but-for causation ...
Why Regeneron's Price May Soon Break Out
Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...
Regeneron Gets Court to Impose Tougher Kickback Standard (1)
Regeneron Pharmaceuticals Inc. convinced the First Circuit to impose a higher causation standard in the government’s False Claims Act case alleging a drug kickback scheme, according to a Tuesday ...